Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) — The “Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) – Global Forecast to 2030” has been added to ResearchAndMarkets.com’s offering.
The global patient-derived xenograft (PDX) model market is forecasted to grow from USD 0.37 billion in 2025 to USD 0.66 billion by 2030, driven by a CAGR of 12.5%.
The report details product development, market expansion opportunities, and provides a thorough competitive assessment of key players, including BioDuro (US) and Aragen Life Sciences (India). This extensive coverage aids in understanding market dynamics and positioning business strategies accordingly.
The demand for PDX models in oncology research, due to their effectiveness in replicating human tumor biology, remains a primary driving force. These models are pivotal in assessing drug efficacy, identifying biomarkers, and informing personalized treatment strategies. The integration of advanced technologies like next-generation sequencing with PDX platforms is further enhancing their utility. However, factors such as high costs, development time, and ethical concerns pose challenges to widespread adoption.
Orthotopic Implantation Segment Growth
The orthotopic implantation method is anticipated to register the highest CAGR during the forecast period. Its superiority in mimicking the natural tumor environment, through exact representation of tumor-stroma interactions, and disease progression contributes to its high demand. Orthotopic models provide improved translational relevance and predictive accuracy, proving beneficial in evaluating drug efficacy and resistance.
With the increasing emphasis on targeted therapies and immunotherapies, the demand for orthotopic models has surged. Advances in imaging and microsurgical techniques have improved reproducibility, making these models widely accessible for preclinical studies. The collective advantages drive this segment’s growth globally.
Gastrointestinal Tumor Model Market Dominance
The gastrointestinal tumor model segment holds the largest market share, owing to the prevalence of GI malignancies, such as colorectal and gastric cancers. These models offer faithful preservation of tumor heterogeneity, making them invaluable in therapeutic evaluation. The rise in precision medicine and focused clinical trials on GI cancers bolster the demand for these robust models.
Continual improvements in engraftment techniques and molecular profiling enhance the effectiveness of gastrointestinal PDX models, maintaining their dominant market position.
U.S. Market Growth
The United States is positioned to experience the highest growth rate in the PDX model market. This growth is underpinned by the presence of leading pharmaceutical enterprises, substantial research infrastructure, and vigorous oncology research initiatives. The drive towards personalized medicine and increasing cancer prevalence contribute significantly to the growing demand for PDX models.
Moreover, extensive investment in translational research, combined with collaborative efforts between academia and industry, propels market expansion. Supportive regulatory frameworks and advanced laboratory facilities further enhance the U.S. market’s strength in this sector.
Key Companies and Research Coverage
Leading companies in the PDX model market include JSR Corporation (Japan), WuXi AppTec (China), The Jackson Laboratory (US), Charles River Laboratories (US), and Taconic Biosciences, Inc. (US). This research report categorizes the market by implantation method, type, tumor type, application, end-user, and region.
The report comprehensively analyzes the drivers, restraints, challenges, and opportunities influencing market growth. It provides insights on strategic initiatives and new product launches by key industry players. Further, a competitive assessment includes a detailed evaluation of leading market players and emerging startups.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 367 |
| Forecast Period | 2025 – 2030 |
| Estimated Market Value (USD) in 2025 | $0.37 Billion |
| Forecasted Market Value (USD) by 2030 | $0.66 Billion |
| Compound Annual Growth Rate | 12.5% |
| Regions Covered | Global |
Market Dynamics
Drivers
- Growing Demand for Immuno-Oncology and Complex Biologics
- Rising Preference for Humanized Pdx Models
- Focus on Government-Funded Initiatives for Cancer Research
Challenges
- Limitations of Humanized Mouse Models
Opportunities
- Increasing Preference for Personalized Medicines in Oncology
- Growing Demand for Cdx Models for Pdx Model Vendors
Industry Trends
- Porter’s Five Forces Analysis
- Ecosystem Analysis
- Value Chain Analysis
- Pricing Analysis
- Macroeconomic Outlook
- Investment & Funding Scenario
- Patent Analysis
Case Studies
- Imaging-Ready Orthotopic Pdx for Pediatric Brain Tumors
- Host-Strain Selection Using Breast Cancer Pdx
- Resistance-Anchored Pdx Panel to Design Mouse Clinical Trial
Company Profiles
- Charles River Laboratories
- The Jackson Laboratory
- Inotiv
- Jsr Corporation
- Genoway
- Wuxi Apptec + Wuxi Biologics
- Biocytogen Pharmaceuticals Co. Ltd.
- Taconic Biosciences, Inc.
- Oncodesign Services (Oncodesign Precision Medicine)
- Champions Oncology, Inc.
- Pharmaron
- Syngene International Limited
- Labcorp
- Eurofins Scientific
- Vitalstar Biotechnology Co. Ltd.
- Creative Animodel
- Joinn Laboratories (China) Co. Ltd.
- Creative Biolabs
- Aragen Life Sciences Ltd.
- Pharmtest Services
- Lide Shanghai Biotech Co. Ltd.
- Certis Oncology Solutions
- Innoser
- Shanghai Chempartner
- Ivrs Ab
For more information about this report visit https://www.researchandmarkets.com/r/7liakr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Patient Derived Xenografts/PDX Models Market
